Evidence map›Paper›PMID 40806542›Full record

ArticleInternational journal of molecular sciences2025

Variations in Circulating Tumor Microenvironment-Associated Proteins in Non-Muscle Invasive Bladder Cancer Induced by Mitomycin C Treatment.

Benito Blanco Gómez, Francisco Javier Casas-Nebra, Daniel Pérez-Fentes, Susana B Bravo, Laura Rodríguez-Silva, Cristina Núñez

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Benito Blanco GómezUrology Division, Lucus Augusti University Hospital (HULA), Servizo Galego de Saúde (SERGAS), 27002 Lugo, Spain.
Francisco Javier Casas-NebraUrology Division, Lucus Augusti University Hospital (HULA), Servizo Galego de Saúde (SERGAS), 27002 Lugo, Spain.
Daniel Pérez-FentesUrology Division, University Clinical Hospital of Santiago de Compostela (CHUS), Servizo Galego de Saúde (SERGAS), 15706 Santiago de Compostela, Spain.ORCID 0000-0001-6348-8646
Susana B BravoProteomic Unit, Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago de Compostela (CHUS), 15706 Santiago de Compostela, Spain.ORCID 0000-0001-7615-3079
Laura Rodríguez-SilvaInorganic Chemistry Department, Faculty of Sciences, Campus Terra, University of Santiago de Compostela, 27002 Lugo, Spain.ORCID 0000-0002-4071-3967
Cristina NúñezInorganic Chemistry Department, Faculty of Sciences, Campus Terra, University of Santiago de Compostela, 27002 Lugo, Spain.

Funding

Instituto de Salud Carlos III PI22/00025Ministerio de Ciencia, Innovación y Universidades CNS2024-154855
6 · The paper itself

Abstract

Mitomycin C (MMC) is a widely employed chemotherapeutic agent, particularly in non-muscle invasive bladder cancer (NMIBC), where it functions by inducing DNA cross-linking and promoting tumor cell apoptosis. However, the tumor microenvironment (TME) significantly influences the therapeutic efficacy of MMC. Among the key regulators within the TME, the complement system and the coagulation pathway play a crucial role in modulating immune responses to cancer therapies, including MMC. This article explores the interaction between platinum nanoparticles (PtNPs) with human serum (HS) of NMIBC patients (T1 and Ta subtypes) at three different points: before the chemotherapy instillation of MMC (

Indexed as

MitomycinTumor MicroenvironmentUrinary Bladder NeoplasmsAgedBiomarkers, TumorFemaleHumansMaleMetal NanoparticlesMiddle AgedNon-Muscle Invasive Bladder NeoplasmsPlatinumProteomicsBiomarkers, TumorMitomycinPlatinumcomplement systemmitomycin C (MMC)non-muscle invasive bladder cancer (NMIBC)platinum nanoparticles (PtNPs)protein corona (PC)SWATH-MStumor microenvironment (TME)

Identifiers

PMID40806542
PMCPMC12347783

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.